These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 36816964

  • 1. Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia.
    Zhou R, Liang T, Li T, Huang J, Chen C.
    Front Oncol; 2023; 13():1070069. PubMed ID: 36816964
    [Abstract] [Full Text] [Related]

  • 2. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Mondelaers V, Ferster A, Uyttebroeck A, Brichard B, van der Werff Ten Bosch J, Norga K, Francotte N, Piette C, Vandemeulebroecke K, Verbeke C, Schmidt S, Benoit Y, Lammens T, De Moerloose B.
    Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
    [Abstract] [Full Text] [Related]

  • 3. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
    Vieira Pinheiro JP, Müller HJ, Schwabe D, Gunkel M, Casimiro da Palma J, Henze G, von Schütz V, Winkelhorst M, Würthwein G, Boos J.
    Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
    [Abstract] [Full Text] [Related]

  • 4. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
    Aslanian AM, Kilberg MS.
    Biochem J; 2001 Aug 15; 358(Pt 1):59-67. PubMed ID: 11485552
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
    Chien WW, Le Beux C, Rachinel N, Julien M, Lacroix CE, Allas S, Sahakian P, Cornut-Thibaut A, Lionnard L, Kucharczak J, Aouacheria A, Abribat T, Salles G.
    Sci Rep; 2015 Jan 28; 5():8068. PubMed ID: 25626693
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
    Su N, Pan YX, Zhou M, Harvey RC, Hunger SP, Kilberg MS.
    Pediatr Blood Cancer; 2008 Feb 28; 50(2):274-9. PubMed ID: 17514734
    [Abstract] [Full Text] [Related]

  • 10. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI.
    Clin Cancer Res; 2004 Aug 15; 10(16):5335-41. PubMed ID: 15328169
    [Abstract] [Full Text] [Related]

  • 11. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP.
    Ann N Y Acad Sci; 2014 Nov 15; 1329():81-92. PubMed ID: 25098829
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon PS, Panosyan EH, Avramis IA, Avramis VI, Rubin J, Ettinger LJ, Seibel NL, Dhall G.
    Cancer; 2015 Dec 01; 121(23):4205-11. PubMed ID: 26308766
    [Abstract] [Full Text] [Related]

  • 15. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP, Di Cataldo A, Ragusa R, Meli C, Lo Nigro L.
    J Clin Oncol; 1995 Feb 01; 13(2):339-44. PubMed ID: 7844595
    [Abstract] [Full Text] [Related]

  • 16. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
    Gupta S, Wang C, Raetz EA, Schore R, Salzer WL, Larsen EC, Maloney KW, Mattano LA, Carroll WL, Winick NJ, Hunger SP, Loh ML, Devidas M.
    J Clin Oncol; 2020 Jun 10; 38(17):1897-1905. PubMed ID: 32275469
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
    Takahashi H, Koh K, Kato M, Isobe K, Yasui N, Mori M, Akiyama K, Kikuchi A, Hanada R.
    Rinsho Ketsueki; 2013 Apr 10; 54(4):370-7. PubMed ID: 23666219
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.